NCT03888365 - Patient Global Impression Questions for Activity-Induced Symptoms in Participants With PAH | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

April 1, 2019

Primary Completion Date

September 19, 2019

Study Completion Date

September 19, 2019

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Treprostinil

Treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.

DRUG

Non-Treprostinil PAH Medications

Non-treprostinil treatment will be at the discretion of the participant's physician, and determined on an individual basis.

Trial Locations (10)

The Mount Sinai Hospital, New York

Pulmonary Health Physicians, PC, Fayetteville

University of North Carolina at Chapel Hill, Chapel Hill

Pulmonary & Critical Care of Atlanta, Atlanta

St. Francis Sleep, Allergy & Lung Institute, Clearwater

The University of Alabama at Birmingham, Birmingham

Kentuckiana Pulmonary Associates, Louisville

Cedars-Sinai Medical Center, Beverly Hills

Santa Barbara Pulmonary Associates, Santa Barbara

Rhode Island Hospital, Providence